Literature DB >> 25920449

A CD63(+ve)/c-kit(+ve) stem cell population isolated from the mouse heart.

Latifa S Abdelli1, Dinender K Singla.   

Abstract

Cardiac cell regeneration from endogenous cardiac stem cells (CSCs) following MI is rather low. Therefore, identifying mechanisms to boost endogenous CSC activation and participation in cardiac repair appears to be the most promising strategy for MI patients. We previously engineered tissue inhibitor of metalloproteinases-1 (TIMP-1) overexpressing embryonic stem (ES-TIMP-1) cells and transplanted them into the infarcted murine heart. Collected data demonstrated that TIMP-1 enhanced transplanted ES cell engraftment, survival and differentiation into cardiac myocytes post-transplantation. Therefore, we postulated that there may be a new stem cell population present in the heart that is regulated by extracellular protein TIMP-1. Furthermore, we hypothesized that this cell population has a potential for cell proliferation and differentiation into cardiac cell types. Therefore, we isolated CSCs from 4 weeks old C57BL/6 mice and cultured them in vitro in presence of ESCM, ES-TIMP-1-CM or TIMP-1. Our immunostaining data demonstrated the existence of a novel CSC subpopulation, CD63(+ve)/c-kit(+ve). When treated with TIMP-1, these cells showed significantly (p < 0.05) increased proliferation rates compared to control cells, enhanced TIMP-1 receptor (CD63), along with improved expression of phospho and total β-catenin proteins as demonstrated by Western blot analysis. Next, we demonstrate significantly (p < 0.05) improved cardiac myocyte, vascular smooth muscle cell, and endothelial cell differentiation. Furthermore, our RT-PCR data shows increase in cardiac gene (GATA-4, Mef2C, and Nkx-2.5) expression when compared to ESCM and control cells. Collectively, these data, for the first time, establish the existence of a new CD63(+ve)/c-kit(+ve) CSC subpopulation that has a significant potential for proliferation and differentiation into cardiac cell types once stimulated with TIMP-1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25920449     DOI: 10.1007/s11010-015-2428-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  21 in total

1.  Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.

Authors:  Ki-Kyung Jung; Xu-Wen Liu; Rosemarie Chirco; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

2.  TGF-β2 treatment enhances cytoprotective factors released from embryonic stem cells and inhibits apoptosis in infarcted myocardium.

Authors:  Dinender K Singla; Reetu D Singla; Stephanie Lamm; Carley Glass
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-04       Impact factor: 4.733

3.  Astrocytic tissue inhibitor of metalloproteinase-1 (TIMP-1) promotes oligodendrocyte differentiation and enhances CNS myelination.

Authors:  Craig S Moore; Richard Milner; Akiko Nishiyama; Ricardo F Frausto; David R Serwanski; Roberto R Pagarigan; J Lindsay Whitton; Robert H Miller; Stephen J Crocker
Journal:  J Neurosci       Date:  2011-04-20       Impact factor: 6.167

4.  Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling.

Authors:  Virginia Egea; Stefan Zahler; Nicole Rieth; Peter Neth; Tanja Popp; Kai Kehe; Marianne Jochum; Christian Ries
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-05       Impact factor: 11.205

5.  CD63 is an essential cofactor to leukocyte recruitment by endothelial P-selectin.

Authors:  Emily L Doyle; Victoria Ridger; Francesco Ferraro; Mark Turmaine; Paul Saftig; Daniel F Cutler
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

6.  mef2c is activated directly by myogenic basic helix-loop-helix proteins during skeletal muscle development in vivo.

Authors:  Evdokia Dodou; Shan-Mei Xu; Brian L Black
Journal:  Mech Dev       Date:  2003-09       Impact factor: 1.882

7.  Evidence for cardiomyocyte renewal in humans.

Authors:  Olaf Bergmann; Ratan D Bhardwaj; Samuel Bernard; Sofia Zdunek; Fanie Barnabé-Heider; Stuart Walsh; Joel Zupicich; Kanar Alkass; Bruce A Buchholz; Henrik Druid; Stefan Jovinge; Jonas Frisén
Journal:  Science       Date:  2009-04-03       Impact factor: 47.728

8.  Cardiac differentiation of pluripotent stem cells.

Authors:  Kristiina Rajala; Mari Pekkanen-Mattila; Katriina Aalto-Setälä
Journal:  Stem Cells Int       Date:  2011-04-04       Impact factor: 5.443

9.  Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.

Authors:  Charlotte Kopitz; Michael Gerg; Obul Reddy Bandapalli; Dilek Ister; Caroline J Pennington; Stephanie Hauser; Christin Flechsig; Hans-Willi Krell; Dalibor Antolovic; Keith Brew; Hideaki Nagase; Manfred Stangl; Claus W Hann von Weyhern; Björn L D M Brücher; Karsten Brand; Lisa M Coussens; Dylan R Edwards; Achim Krüger
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

10.  Notch-1 mediated cardiac protection following embryonic and induced pluripotent stem cell transplantation in doxorubicin-induced heart failure.

Authors:  Hilda Merino; Dinender K Singla
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

View more
  3 in total

1.  PTEN inhibitor VO-OHpic attenuates inflammatory M1 macrophages and cardiac remodeling in doxorubicin-induced cardiomyopathy.

Authors:  Taylor A Johnson; Dinender K Singla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-10       Impact factor: 4.733

2.  Single-cell analysis of the fate of c-kit-positive bone marrow cells.

Authors:  Anna Czarna; Fumihiro Sanada; Alex Matsuda; Junghyun Kim; Sergio Signore; João D Pereira; Andrea Sorrentino; Ramaswamy Kannappan; Antonio Cannatà; Toru Hosoda; Marcello Rota; Filippo Crea; Piero Anversa; Annarosa Leri
Journal:  NPJ Regen Med       Date:  2017-10-16

3.  Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer.

Authors:  Cathrine Nordgaard; Sophia Doll; Ana Laura de Souza Almeida Matos; Mikkel Høeberg; Julhash Uddin Kazi; Stine Friis; Jan Stenvang; Lars Rönnstrand; Matthias Mann; José Manuel Afonso Moreira
Journal:  Mol Oncol       Date:  2019-10-24       Impact factor: 6.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.